BRIEF-MBX Biosciences Announces Positive Phase 1 Topline Results For MBX 1416 To Treat Post-Bariatric Hypoglycemia

Reuters01-07 20:17

Jan 7 (Reuters) - MBX Biosciences Inc :

* MBX BIOSCIENCES ANNOUNCES POSITIVE PHASE 1 TOPLINE RESULTS FOR MBX 1416 FOR THE TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA

* MBX BIOSCIENCES INC - 1416 GENERALLY WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE

* MBX BIOSCIENCES - PENDING ALIGNMENT WITH FDA, PHASE 2 STUDY OF MBX 1416 IN PATIENTS WITH PBH ANTICIPATED IN SECOND HALF OF 2025

Source text: Further company coverage:

((Reuters.Brief@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501208860?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501208860","market":"us","top_or_hot":-1,"title":"BRIEF-MBX Biosciences Announces Positive Phase 1 Topline Results For MBX 1416 To Treat Post-Bariatric Hypoglycemia","media":"Reuters","content":"<html><body><p>Jan 7 (Reuters) - <a href=\"https://laohu8.com/S/MBX\">MBX Biosciences</a> Inc   :</p><p>   * MBX BIOSCIENCES ANNOUNCES POSITIVE PHASE 1 TOPLINE RESULTS FOR MBX 1416 FOR THE TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA</p><p>   * MBX BIOSCIENCES INC - 1416 GENERALLY WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE</p><p>   * MBX BIOSCIENCES - PENDING ALIGNMENT WITH FDA, PHASE 2 STUDY OF MBX 1416 IN PATIENTS WITH PBH ANTICIPATED IN SECOND HALF OF 2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Brief@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-MBX Biosciences Announces Positive Phase 1 Topline Results For MBX 1416 To Treat Post-Bariatric Hypoglycemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-MBX Biosciences Announces Positive Phase 1 Topline Results For MBX 1416 To Treat Post-Bariatric Hypoglycemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-07 20:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 7 (Reuters) - MBX Biosciences Inc   :   * MBX BIOSCIENCES ANNOUNCES POSITIVE PHASE 1 TOPLINE RESULTS FOR MBX 1416 FOR THE TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA   * MBX BIOSCIENCES INC - 1416 ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MBX","symbol_name":"MBX Biosciences","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2501208860","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501208860","pubTimestamp":1736252258,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 7  - MBX Biosciences Inc   :   * MBX BIOSCIENCES ANNOUNCES POSITIVE PHASE 1 TOPLINE RESULTS FOR MBX 1416 FOR THE TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA   * MBX BIOSCIENCES INC - 1416 GENERALLY WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE   * MBX BIOSCIENCES - PENDING ALIGNMENT WITH FDA, PHASE 2 STUDY OF MBX 1416 IN PATIENTS WITH PBH ANTICIPATED IN SECOND HALF OF 2025Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MBX":"MBX Biosciences","BK4007":"制药","BK4212":"包装食品与肉类","POST":"Post Holdings"},"translate_title":"简介-MBX Biosciences宣布MBX 1416治疗减肥后低血糖症的1期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBX":1,"POST":1},"content_text":"Jan 7 (Reuters) - MBX Biosciences Inc   :   * MBX BIOSCIENCES ANNOUNCES POSITIVE PHASE 1 TOPLINE RESULTS FOR MBX 1416 FOR THE TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA   * MBX BIOSCIENCES INC - 1416 GENERALLY WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE   * MBX BIOSCIENCES - PENDING ALIGNMENT WITH FDA, PHASE 2 STUDY OF MBX 1416 IN PATIENTS WITH PBH ANTICIPATED IN SECOND HALF OF 2025Source text:    Further company coverage:    ((Reuters.Brief@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501208860"}